Torchmark Corporation (now Globe Life Inc.) — 2014 Form 10-K
Entity and period: The supplied filing is Torchmark Corporation’s annual report for the fiscal year ended December 31, 2014; Globe Life And Accident Insurance Company was a Torchmark subsidiary. This is an annual filing, not a standalone Q4 filing. Unless noted, financial amounts below are in U.S. dollars.
Business context and reporting period
Torchmark was an insurance holding company focused primarily on individual life and supplemental health insurance for middle-income households. Its main distribution channels included exclusive and independent agents and direct response marketing. The company reported life, health, Medicare Part D, annuity, and investment segments; Medicare Part D became a separately reported segment in 2014, with prior periods adjusted for comparison.
Financial performance and condition
| Metric | 2014 | 2013 | Change or context |
|---|---|---|---|
| Total revenue | $3.964 billion | $3.772 billion | Up 5% |
| Total premiums | $3.209 billion | $3.052 billion | Up 5% |
| Net investment income | $729.2 million | $709.7 million | Up 3% |
| Net income | $542.9 million | $528.5 million | Up 3% |
| Diluted earnings per share | $4.09 | $3.79 | Up 8%; share repurchases contributed to per-share growth |
| Cash provided by operations | $864.7 million | $1.119 billion | Down approximately 23% |
| Total assets | $20.215 billion | $18.192 billion | Up approximately 11% |
| Total debt, carrying value | $1.231 billion | $1.220 billion | Includes $238.4 million short-term debt |
| Shareholders’ equity | $4.697 billion | $3.776 billion | Increase was substantially affected by unrealized fixed-maturity gains |
- Life premium rose 4% to $1.966 billion; life underwriting margin increased 2% to $556.5 million, while margin as a share of premium eased to 28% from 29%.
- Health premium, excluding Medicare Part D, increased slightly to $869.4 million; underwriting margin rose 1% to $199.3 million, or 23% of premium.
- Medicare Part D premium increased 16% to $347.8 million, but its underwriting margin fell 23% to $27.3 million; margin declined to 8% of premium from 12%.
- Excess investment income rose 3% to $225.1 million, or $1.70 per diluted share. Low investment yields and rising required interest on policy liabilities remained constraints.
- At year-end, cash and short-term investments were $81.9 million and fixed maturities had a fair value of $14.5 billion. Approximately 96% of fixed maturities were investment grade, with a weighted-average quality rating of A-.
- Insurance subsidiaries’ aggregate risk-based capital ratio was approximately 326%, against management’s 325% target. Parent-company liquidity included $314 million of available capacity under its credit facility at year-end.
Material changes versus prior comparable period
- Net income rose by $14.5 million, while after-tax segment profits increased about $3.8 million. Life underwriting remained the largest earnings contributor.
- Medicare Part D results weakened despite premium growth. Management attributed the decline mainly to unexpectedly costly Hepatitis C drugs mandated after 2014 pricing was set, Affordable Care Act taxes, and higher drug costs related to rebate changes.
- Operating cash flow declined from 2013. The filing attributes part of the pressure to increased receivables, including $154 million expected from 2015 Medicare Part D risk-sharing, pass-through, and drug-rebate collections.
- Net unrealized investment gains increased substantially: fixed maturities were in a $1.7 billion net unrealized gain position at year-end, compared with $390 million in 2013. This helped lift equity; management cautioned that fair-value movements create GAAP equity volatility and do not represent realized operating income.
- Annualized premium in force increased to $3.308 billion from $3.166 billion. Life rose 5%; health rose 4%.
Outlook, commentary, risks, and unusual items
- 2015 outlook: Management expected approximately $473 million of dividends from insurance subsidiaries and $355–$365 million of parent-company excess cash flow. It expected Part D margins to be flat to slightly lower, citing the 2015 enrollee risk profile and claims history. Management did not expect the 2014 Hepatitis C claims impact to recur at the same level, noting 2015 pricing reflected drug costs and enrollment included fewer auto-enrollees.
- Management expected low interest rates to continue to pressure portfolio yields, but anticipated only modest average-yield declines; it estimated that 1%–2% of fixed maturities would run off annually over the next five years. No formal company-wide earnings guidance was provided in the supplied filing text.
- Investment and liquidity risks include interest-rate changes, credit downgrades or defaults, and reliance on regulated dividends from insurance subsidiaries. Other key risks include mortality, morbidity and lapse experience, agent recruitment and retention, competition, regulation and rate approvals, litigation, cybersecurity, and catastrophic events.
- 2014 unusual items included $8.2 million of administrative settlements, after tax $5.3 million, concerning benefits for deaths in prior years where claims had not been filed; $3.7 million of litigation accruals, after tax $2.4 million; and a $1.3 million investment-litigation settlement receipt, after tax $0.9 million. These items are not included in management’s segment operating analysis.
- Unclaimed-property audits were underway in 47 states concerning policies and a limited number of annuity contracts. No state financial assessment or liability had been indicated; the company could not estimate possible administrative penalties or other related exposure. Management said pending litigation was not expected to have a material adverse effect, while acknowledging the possibility of unpredictable punitive awards.
- Standard & Poor’s revised Torchmark’s capital-position outlook to negative in August 2014. Management said it expected the consolidated RBC ratio to remain at least 325% and did not anticipate changing the share-repurchase program in response.
- The company repurchased 7.2 million shares for $375 million under its program and declared $0.51 per share in dividends for 2014. Deloitte & Touche issued unqualified opinions on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Confirm the issuer and reporting scope: this filing is Torchmark Corporation’s 2014 10-K, not a standalone Globe Life Inc. filing.
- Reconcile reported net income with segment profits and the unusual items, and assess the contribution of realized investment gains.
- Review Medicare Part D claims, enrollee mix, pricing assumptions, and the 2015 outlook against subsequent reported results.
- Examine the decline in operating cash flow, Part D-related receivables and collection timing, and the parent’s dependence on subsidiary dividends.
- Assess the investment portfolio’s long duration, credit exposure, unrealized gains, and sensitivity to interest-rate and spread changes.
- Review the 326% RBC ratio against the 325% target, the S&P negative outlook, debt maturities, and continued capital returns through buybacks and dividends.
- Track the multistate unclaimed-property audits and any developments in litigation, administrative settlements, or potential penalties.